相关实验视频
Updated: Jul 16, 2025
08:05
Murine Model of Allergen Induced Asthma
Published on: May 14, 2012
40.3K
在体内识别和优先考虑喘的治疗点
Ishita Mallick1, Pradnya Panchal1, Smita Kadam1
1Innoplexus Consulting Pvt. Ltd, 7th Floor, Midas Tower, Next to STPI Building, Phase 1, Hinjewadi Rajiv Gandhi Infotech Park, Hinjawadi, Pune, Maharashtra, 411057, India.
Scientific reports
|September 22, 2023
概括
这项研究确定了互白素-13 (IL-13) 作为喘的关键治疗标,现有治疗方法可用. 对于进一步的喘研究,HMOX1和ITGAM等新型目标也出现了.
科学领域:
- 肺部医学 肺部医学
- 免疫学 免疫学 免疫学
- 生物信息学是一种生物信息学.
背景情况:
- 喘是一种慢性呼吸道疾病,影响全球超过2.62亿人,其特点是炎症和可变的症状.
- 喘的严重程度和治疗反应取决于临床特征的复杂相互作用.
- 确定精确的治疗目标对于有效的喘管理至关重要.
研究的目的:
- 通过分析科学文献和OMIC数据,识别和评估喘的关键治疗点.
- 优先考虑实验验证和潜在的喘药物开发的目标.
主要方法:
- 利用Ontosight® Discover工具,从科学文件中注释喘相关的基因和蛋白质.
- 应用生物信息学和机器学习分析喘患者的OMIC数据集 (基因组学,转录组学).
- 根据治疗潜力的生物参数评估确定目标.
主要成果:
- 从各种数据来源分析了总共18419个潜在目标.
- 鉴定了互白素-13 (IL-13) 作为目前批准的药物的首要目标.
- 突出了TNF,VEGFA,IL-18作为需要进一步临床研究的有希望的目标.
- 揭示了新的潜在目标,包括HMOX1,ITGAM,DDX58,SFTPD和ADAM17用于实验验证.
结论:
- IL-13是喘的验证和重要的治疗标.
- 喘治疗的TNF,VEGFA和IL-18需要进一步的临床探索.
- 像HMOX1,ITGAM,DDX58,SFTPD和ADAM17这样的新目标代表了未来喘研究和治疗开发的有希望的途径.
更多相关视频
相关概念视频
01:30Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
326
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
326
01:20Asthma: Pathogenesis and Management
433
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
433
01:26Asthma-II: Pathophysiology and Classification
2.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.7K
01:29Asthma-I: Introduction
2.7K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.7K
01:19Antiasthma Drugs: Leukotriene Modifiers
338
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
338